The growth in biopharmaceuticals is creating an unprecedented increase in demand for cell culture products. Cell culture techniques have been used in biological sciences for more than 50 years; however, cell culture techniques have been applied to production systems for only about 26 years. The cell culture industry, which began in the late 1980s from the utilization of recombinant DNA technology and cell hybridization, is today a major underpinning of the biopharmaceutical market.
The choice of cells to use in biopharmaceutical production depends on a number of factors, some technical and some economic. Bacteria and yeast, for instance, are relatively simple to grow. Each cell of a bacterium or yeast is an independent organism capable of its own metabolism. Yeasts and bacteria have fairly simple nutritional needs and grow well suspended in a liquid medium, as well as in large fermentors.
This report is focused on cell culture used in the research and production of biopharmaceuticals. In the pharmaceutical industry, cell culture is a major foundation of biopharmaceutical development, bioprocessing and manufacturing. Biopharmaceutical products are developed from large, complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. As growing cells for biopharmaceutical production is slow, expensive and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals. Forecasts and current market sizing are provided in three specific segments:
In addition to a thorough discussion of the technologies and techniques currently employed and emerging in the cell culture area, Kalorama's exhaustive report provides specific information on:
The report contains a discussion of the preferences in media types vying for dominance in the market, including the following:
The report also contains a discussion of Major Trends Impacting the Market: stem cell research (including plans of major companies), cell culture-based vaccine Production and generic biopharmaceuticals and Profiles of Leading Suppliers and information about M&A activities in recent years
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company and cell culture supply company representatives included marketing directors, division managers, and product representatives.